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ment was rapid. Median time to achieve an absolute neutrophil
count 	500 cells/L was post-transplant day (D) 9 (range,
8–11). Full donor lymphoid chimerism (95% by VNTR-PCR on
CD3 sorted peripheral blood) was achieved in all pts (18/21 D 
14; 21/21 D  28). Immune recovery was brisk and sustained.
CD4, CD8, and NK cell numbers exceeded those at study entry by
D  28. Serum IL-7 levels were inversely correlated with CD4
counts. B-cell counts approached entry values by D  100. Sub-
stantial numbers of naive (CD45RA/CD62L) CD4 and
CD8 T cells were detected on D  28, suggestive of early
recovery of thymic function. Conclusions: Targeted pre-trans-
plant immune depletion and NMSCT results in rapid, sustained
donor-derived engraftment and immune reconstitution in pediatric
pts with malignancy. Early immune recovery includes naive T cell
subsets and B cells. Despite potential obstacles in pediatric pts,
NMSCT conditioning can induce rapid engraftment and immue
reconstitution, which may allow application of this novel platform
to direct allogeneic anti-tumor immune responses in high-risk
childhood cancers (Table 1).
Table 1. Immune Depletion and Recovery (Mean Cell Counts/L)
Pre Post D  0 D  28 D  60 D  100 D  180
CD4 304 156 27 394 376 313 413
CD8 344 226 4 561 684 635 544
Naive CD4 69 35 20 123 64 100 118
Naive CD8 130 49 87 192 137 206 169
B cell 115 3 4 12 94 106 200
NK cell 87 111 1 274 222 154 130
Data represent mean cell counts/L; Pre: entry; Post: after induc-
tion; D: post-transplant day.
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PERIPHERAL T CELL APOPTOSIS AFFECTS IMMUNE RECONSTITUTION
AFTER ALLOGENEIC BMT
Alpdogan, O.1, McGoldrick, S.1, Lu, S.1, Patel, N.1, Suh, D.1,
Smith, O.M.1, van den Brink, M.R.M.1 Memorial Sloan-Kettering
Cancer Center, New York, NY.
Post-transplant T cell deﬁciency (especially in adults) is related to
impaired thymus-dependent lymphopoiesis. However, others and
we have previously found in human and murine studies that pe-
ripheral T cell apoptosis is increased in recipients of an allogeneic
bone marrow transplantation (allo BMT). We used murine BMT
models to further analyze peripheral T cell apoptosis in recipients
of a T cell-depleted (TCD) or T cell-replete BMT. In recipients of
a TCD BMT, we found that donor derived T cells had a high
percentage of apoptotic cells (Annexin-V) in both syngeneic and
allogeneic hosts when analyzed at days 14 and 28 after BMT.
Cleaved caspase-3 levels in these T cells were also increased in
comparison with non-transplanted controls. Both CD4 and
CD8 memory (CD44hi) T cells had a higher percentage of
apoptotic cells compared to naive (CD44lo) cells. This was asso-
ciated with decreased levels of intracellular Bcl-2 in de novo gen-
erated T cells from both young and old recipients of an allo
TCD-BMT. We then transplanted allogeneic hosts with bone
marrow (BM) from RAG-2-eGFP transgenic mice to examine
apoptosis in newly generated T cells (recent thymic emigrants
[RTE]) and found increased apoptotic cells in both eGFPhi and
eGFPlo T cells. This demonstrates that both non-divided (eGF-
Phi) and proliferating (eGFPlo) donor BM derived T cells can
undergo apoptosis in the periphery after TCD-BMT. In recipients
with GVHD, we observed a severe loss of thymic cellularity and
low numbers of BM derived de novo generated T cells with a high
fraction of apoptotic cells. These had very low Bcl-2 expression and
increased caspase 8 and 9 activation. Conversely, alloreactive T
cells (from the mature donor T cells in the allograft) showed
upregulation of Fas expression, higher Bcl-2 levels, less caspase
activity, and contained lower numbers of apoptotic T cells com-
pared to BM derived T cells. Allogeneic recipients receiving donor
BM deﬁcient for Fas, Fas Ligand and TRAIL, or over-expressing
Bcl-2 and Akt had no decrease in donor derived apoptotic T cells,
suggesting that these molecules were not absolutely required for
post-transplant peripheral T cell apoptosis. We conclude that
newly generated donor BM derived T cells have increased periph-
eral T cell apoptosis, especially in older recipients and in recipients
with GVHD, which could be an important factor in the delay of
post-transplant T cell reconstitution.
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IMMUNE RECONSTITUTION AFTER CD8-DEPLETED OR UNMANIPU-
LATED PERIPHERAL BLOOD STEM CELLS TRANSPLANTATION FOL-
LOWING NONMYELOABLATIVE CONDITIONING: RESULTS FROM A
PROSPECTIVE RANDOMIZED TRIAL
Castermans, E.1, Baron, F.1, Willems, E.1, Meuris, N.1,
Schaaf-Lafontaine, N.1, Cheynier, R.2, Geenen, V.1, Sekaly, R.-P.3,
Beguin, Y.1 1. CHU de Liege, Liege, Belgium; 2. Institut Pasteur, Paris,
France; 3. Centre de Recherches du CHUM, Hotel-Dieu, Montreal, QC,
Canada.
Aim of the study: We assessed the impact of CD8-depletion
(performed in an effort to reduce the incidence of acute GVHD)
on immune reconstitution after peripheral blood stem cell trans-
plantation (PBSCT) with nonmyeloablative conditioning consist-
ing of 2 Gy TBI with (n  39) or without (n  11) ﬂudarabine.
Patients and methods: 50 patients were randomised between
CD8-depletion (n  22) and lack of any manipulation (n  28).
Median patient age was 57 (range 36–69) years. Twenty patients
received grafts from HLA-matched related donors and 30 from
unrelated donors. CD8-depletion was performed with the Eligix
system. GvHD prophylaxis consisted of mycophenomate mofetil
(MMF) and cyclosporine (CSP). The different peripheral blood
subpopulations were analyzed by 3-color ﬂow-cytometry on days
28, 40, 60, 80, 100, 120, 180, and 365 after PBSCT. The diversity
of the Vb repertoire in CD4 and CD8 T cells was assessed by
rt-PCR on day 180 after PBSCT. Thymic output was determined
through analyses of sjTRECS by quantitative PCR on days 100 and
365 after PBSCT. The expression of transcription factor Foxp3
was measured by quantitative RT-PCR on days 100 and 365 after
PBSCT in order to assess regulatory T cells population. The
impact of PBSC manipulation on T cell subsets recovery was
analyzed by the Mann-Whitney rank sum test. Results: The me-
dian number of CD34, CD3, CD4, and CD8 cells 
106/kg infused were 4.1, 315, 185, and 131 in the unmanipulated
group versus 3.7 (NS), 110 (P  .001), 94 (P  .002), and 4 (P 
.001) in the CD8-depleted group, respectively.CD8 depletion sig-
niﬁcantly impaired recovery of CD3CD8 T cells on days 100,
120, and 180 after HCT (P  .02, P  .02 and P  .03, respec-
tively), but not those of CD3 T cells, CD3CD4 T cells,
CD45RA T cells, CD19B-cells, or CD56NK cells. CD3T
cell chimerism levels from day 28 to day 80 were also signiﬁcantly
decreased in the CD8-depleted group. The levels of sjTRECS
after HCT correlated with those of CD3CD4CD45RA T
cells (Spearman R  0.41, P  .0034).The diversity of VB reper-
toire among CD4 and CD8 T cells on day 180 was similar
among the 2 groups, as were the sjTRECS and Foxp3 levels.
Conclusions: CD8-depletion of PBSC decreased T cell chimer-
ism levels and recovery of CD8 T cells, but did not affect
recovery of other cell subsets, thymic output, nor Vb repertoire
diversity, suggesting that immune reconstitution the ﬁrst year after
HCT was mainly driven by expansion of mature T cells contained
in the graft.
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OPTIMIZATION OF EXPANSION OF CORD BLOOD T CELLS WITH ANTI-
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Cord blood (CB) transplantation in adults is limited by low cell
dose. This leads to delayed engraftment and delayed immune
reconstitution with susceptibility to infections a major cause of
morbidity and mortality. We hypothesize that the infusion of ex
vivo CB T cells expanded using an anti-CD3/anti-CD28 bead may
provide more rapid immune reconstitution, thereby reducing in-
fectious complications. Prior to initiating a clinical trial, conditions
for ex vivo CB T cell expansion need to be optimized. Variables
investigated include addition of N-acetylcysteine (NAC) to culture
(potentially reducing apoptosis), optimizing levels of interleukin 2
(IL-2), and continuous addition of anti-CD3/anti-CD28 beads to
maintain a bead to cell ratio of 3:1. Methods: CB T cells were
isolated from CB sample using anti-CD3/anti-CD28 paramagnetic
beads and co-cultured with beads for a total of 14–28 days. Com-
parisons included: (1) 0 versus 10 mM NAC; (2) maintained 3:1
bead:cell ratio versus dilution with culture; (3) IL-2 concentration
(0, 20, 200, 2000, and 20,000 IU/mL). Phenotypes were investi-
gated using ﬂow cytometry and T cell receptor diversity measured
by spectratyping. Results: Overall, 300–1200-fold increases in T
cell numbers were achieved. (1) While NAC did not signiﬁcantly
impact cell numbers, ﬂow cytometry suggested cell death was
reduced. (2) Maintaining a constant bead to cell ratio throughout
culture did not improve proliferation. (3) Greatest T cell prolifer-
ation was obtained when 2000 and 20,000 IU/mL IL-2 were used.
At the time of maximal expansion, the majority of the CD4 cells
retained a naive phenotype (CD27CD28). A small proportion of
late stage “effector” cells were present (CD27CD28 or
CCR7CD45RA). CD8 T cell differentiation toward a “mem-
ory” phenotype (CD27CD28 or CD27CD28, or
CCR7CD45RA or CCR7CD45RA) was observed. Signiﬁ-
cantly, the expanded CB T cells retained a polyclonal TCR diver-
sity. Conclusions: These preliminary data suggest that the ex vivo
expansion of CB T cells may yield sufﬁcient numbers of T cells to
potentially improve immune reconstitution in CB recipients and
reduce post-transplant mortality. Studies assessing the functional-
ity of the expanded T cells are currently underway.
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ADOPTIVE TRANSFER OF IN VITRO GENERATED T CELL PRECURSORS
IMPROVES T CELL RECONSTITUTION AND MEDIATES GRAFT-VERSUS-
TUMOR ACTIVITY WITHOUT GRAFT-VERSUS-HOST DISEASE IN ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
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Immunoincompetence after allogeneic hematopoietic stem cell
transplantation (HSCT) particularly affects the T cell lineage re-
sulting in signiﬁcant morbidity and mortality from opportunistic
infections. Recent studies have shown that murine T cells and their
precursors can be generated from hematopoietic stem cells (HSC)
in vitro using OP9 bone marrow stromal cells (H2Kk/H2Kb)
expressing the Notch 1 ligand Delta-like 1 and growth factors. In
this study we determined the effects of adoptively transferred in
vitro generated T cell precursors on T cell reconstitution after
allogeneic HSCT. We selected HSC (Lin-Sca-1hi c-kit) from
mouse bone marrow (BM) of various strains and cultured these
cells on a monolayer of OP9-DL1 cells in the presence of growth
factors. T lineage cell development proved to be strain indepen-
dent and is therefore not MHC restricted in this culture system.
C57BL/6 dervied HSC expanded 2000–5000-fold within 3–4
weeks and consisted of 90–95% CD4-CD8-double negative (DN)
T cell precursors after 16–28 days of culture. We infused these
cells (8106) with T cell depleted (TCD) BM (5 106) or puriﬁed
HSC into allogeneic recipients using minor antigen mismatched
and MHC class I/II mismatched transplant models. Progeny of
OP9-DL1 derived T cell precursors were found in the thymus and
the periphery signiﬁcantly improving thymic cellularity, and thy-
mic and splenic donor T cell chimerism. Combination of T cell
precursor administration and pre-conditioning with keratinocyte
growth factor (KGF) further improved thymic engraftment of
OP9-DL1 derived T cell precursors. T cell receptor repertoire and
proliferative response to foreign antigen of OP9-DL1 derived
mature T cells were intact. Moreover, Th1-type cytokine secretion
of OP9-DL1 derived splenic T cells after stimulation with PMA/
ionomycin was better than that of BM or HSC derived donor T
cells. Progeny of OP9-DL1-derived T cell precursors remained
detectable for at least 60 days after transplant with intact cytokine
production. Administration of in vitro generated T cell precursors
did not induce GVHD but mediated signiﬁcant graft-versus-tumor
(GVT) activity (determined by in vivo bioluminescence imaging)
resulting in a subsequent signiﬁcant survival beneﬁt. We conclude
that the adoptive transfer of OP9-DL1 derived T cell precursors
signiﬁcantly enhances donor T cell reconstitution in allogeneic
HSCT recipients and results in GVT activity in the absence of
GVHD.
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RECONSTITUTION OF IMMUNITY TO ADENOVIRUS (Ad) AFTER PEDI-
ATRIC BONE MARROW TRANSPLANT
Myers, G.D.1, Leen, A.M.1, Buza, E.1, Weiss, H.1, Rooney, C.1,
Heslop, H., Bollard, C.M.1 Center for Cell and Gene Therapy, Baylor
College of Medicine, Houston, TX.
Adenovirus is a signiﬁcant cause of morbidity and mortality in
pediatric HSCT patients. Severity of immune suppression appears
to be the most important risk factor for serious Ad disease. With-
out proven antiviral therapy, cellular immunity is the most effective
protection against Ad disease. To better understand Ad immune
recovery post-BMT, we prospectively monitored viral load, Ad
subtype infection rates, and recovery of Ad cellular immunity in 22
pediatric HSCT patients (ages 14 months–20 years) who received
matched-related (MRD n  6), mismatched related (haplo n  6),
or unrelated donor (MUD n  10) grafts. Real-time PCR (Q-
PCR) provided quantitative measure of Ad viral load and detected
Ad in blood samples from 68% (15/22) of patients on at least one
occasion post SCT. 2/6 MRD recipients had Ad detected in their
blood vs 8/10 MUD and 5/6 haplo patients. 13/16 (81%) of
patients who provided stool samples were ve for Ad on at least
one occasion. Ad subgroup C predominated in blood (93%), while
subgroups varied in stool: A(62%), B(12%), C(62%), D(6%),
E(6%), F/G(44%). 8/16 patients were positive for multiple sub-
types in their stool. Mean Ad-speciﬁc spot forming cells (SFC)/1
106 PBMC as measured by IFNg ELISPOT assay was not signif-
icantly different in the MRD and MUD groups at 3, 6, and 12
months post HSCT (P  .1). At 3 months, MUD patients had
mean 29 SFC/106cells (range: 0–190) versus 27 SFC/106 cells
(range: 0–100) in the MRD group. By 12months, MUD patients
had 63 (0–225) versus 78(17–201) SFC/106 cells in MRD group.
However, immune response to adenovirus was signiﬁcantly de-
layed (P  .005) in Haplo patients at 3months (4 SFC/106cells,
range:0–18) and 12months (23 SFC/106cells, range:0–60). Mor-
tality from adenovirus was 4.5% (1/22). Mean ALC in MUD,
MRD, and Haplo recipients at 12 months were:1901/ul (772–
3728), 2153/ul (948–3280), 1713/ul (1128–2406), respectively
(P 	 .1). Mean CD4 and CD8 counts/l in MUD, MRD, and
Haplo recipients at 12months were: 835 (range:37–1656) and 589
(range:18–2404), 1373 (560–2169) and 530 (332–706), and 1055
(451– 1659) and 398 (178–620), respectively (P 	 .1). In conclu-
sion, our data shows recipients of T cell depleted HSCT products
from haploidentical donors have signiﬁcantly delayed Ad-speciﬁc
cellular immune recovery. Further, ALC does not predict speciﬁc
immune recovery to adenovirus. We have initiated a clinical study
of donor-derived adenovirus-speciﬁc CTL infusions for the pro-
phylaxis and treatment of Ad infection post SCT that will target
this patient population.
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